Clinical Trial Update: Randomized Trial Comparing Efficacy of Adalimumab, Anakinra and Tocilizumab in Non-infectious Refractory Uveitis [Phase 2]

View source ↗

Summary

This update reports the completion of a Phase 2 randomized trial comparing adalimumab, anakinra, and tocilizumab for non-infectious refractory uveitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveitis

Drugs mentioned

• Actemra (tocilizumab)
• Humira (adalimumab)
• KINERET (ANAKINRA)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Uveitis, Biotherapy | Phase 2 | Status: COMPLETED